%0 Journal Article
%T Peginterfer o 汐2-a na co-infec  o VHB --- VH delta: Um caso de duplo sucesso terap那utico Peginterferon_2-a in HBV   HVD coinfection: A case of double therapeutic success
%A Liliana Santos
%A Gonˋalo Ramos
%A Isabel Redondo
%A Rita Cˋrte-Real
%J Jornal Portugu那s de Gastrenterologia
%D 2012
%I Sociedade Portuguesa de Gastrenterologia
%X O v赤rus da hepatite D (VHD) 谷 um v赤rus sat谷lite, que necessita do v赤rus da hepatite B (VHB) para a sua replica  o. Na maioria dos casos, o VHD suprime a replicac  o do VHB e, nestas circunstancias, est芍 recomendado o tratamento com Interfer o. Nos doentes em que n o se observa resposta virol車gica ap車s o 1.  ano de terap那utica, o seu prolongamento pode aumentar a taxa de resposta virol車gica sustentada. Caso cl赤nico: Homem, 42 anos, com hepatite cr車nica B, anti-HBe positivo e baixa carga viral. Apresentava aminotransferases aumentadas que persistiram, mesmo ap車s negativa  o do ADNVHB. A positividade da fra  o IgM do AcVHD conduziu ao diagn車stico de co-infec  o VHB-VHD. Foi tratado com PegInterfe o _-2a durante 102 semanas. Observou-se normaliza  o das aminotransferases 角 33.a semana, negativa  o da IgM do AcVHD 角 88.a semana e resposta virol車gica sustentada com perda do AgHB. Coment芍rios: Este caso ilustra a importancia de se manter o tratamento nos doentes com infec  o VHD at谷 resposta virol車gica, uma vez que a cura do VHD pode acompanhar-se da cura da infec  o VHB. Hepatitis D virus (HDV) is a satellite virus which needs hepatitis B virus (HBV) for its replication. In most cases, HDV suppresses HBV replication and in these circumstances the treatment should be with Interferon. In patients that have no virological response after the 1th year of therapy, continuing it will possible increase the virological response and the loss of the HBs antigen. Case report: 42 years old man with chronic HBV, anti-HBe positive and low HBV viral load. He had increased transaminases which had persisted even after HBV-DNA negativation. We performed antibody anti-HDV that came positive and treated the patient with PegInterferon 汐-2a during 102 weeks. We assist to normalization of the transaminases at week 33 and negativation of IgM-HVD at week 88. At the end of the treatment RNA-HDV was negative and the patient lost HBs antigen that persisted over the next sixth months. Comments: This case illustrates the importance of maintaining treatment until HDV virological response since the cure of the HDV may be accompanied by the cure of HBV infection.
%K Co-infec  o
%K VHB
%K VHD
%K Peginterfer o
%K Coinfection
%K HBV
%K HDV
%K Peginterferon
%U http://www.scielo.oces.mctes.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000300010